Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004902 · ClinicalTrials.gov registry record · Phase 2
Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004902 is a Phase 2 study that has completed, run by Northwestern University.
The verdict
NCT00004902, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of tocladesine in treating patients who have recurrent or refractory multiple myeloma.
Interventions
- DRUG tocladesine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-01 |
| Est. Completion | 1999-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004902
The ClinicalTrials.gov registry entry for NCT00004902 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which tocladesine is the first listed.
NCT00004902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004902 about?
NCT00004902 is a clinical study titled "Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of tocladesine in treating patients who have recurrent or refractory multiple myeloma.
What is the current status of trial NCT00004902?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-01. Estimated completion is 1999-11.
What interventions are being tested in trial NCT00004902?
The interventions under investigation include: tocladesine (DRUG).
Who is sponsoring clinical trial NCT00004902?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.